Avalo Therapeutics, Inc.’s AVTX share price has surged by 12.29%, which has investors questioning if this is right time to ...

CAMBRIDGE, Mass. - Eterna Therapeutics (NASDAQ:ERNA), a biotechnology company specializing in cell therapies for solid tumors ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a biotechnology company focused on developing novel cancer treatments, stands at ...

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

After what many considered a “slow” year for IPOs, January has ushered in a string of biotechs filing to go public. But 2024 ...

Shares of biotech Summit Therapeutics ( SMMT 9.31%) skyrocketed 583.7% in 2024, according to data from S&P Global Market ...

Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.

Atalanta Therapeutics is pioneering RNA interference (RNAi) for the treatment of neurological diseases, having developed a proprietary platform that, for the first time enables RNAi to be deployed ...

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology ...